UK pharmacist says Eli Lilly’s Mounjaro price hike a “shock”

Eli Lilly is significantly increasing the UK list price for its blockbuster drug Mounjaro (tirzepatide) effective September 1st, with monthly prices rising from £92-£122 to £133-£330. This decision, influenced by pressures from former US President Donald Trump for drugmakers to raise international prices, is justified by Lilly as addressing global pricing inconsistencies. Mounjaro, which saw Q2 global sales of $5.2 billion (up 68%), will reportedly maintain NHS availability, but analysts suggest this move could signal a broader trend of higher medicine prices in the UK, potentially narrowing the US-UK pricing differential.

Analysis

Eli Lilly is executing a significant price increase for its blockbuster drug Mounjaro in the UK, with the monthly list price escalating from a range of £92-£122 to £133-£330, effective September 1. This strategic repricing follows a period of immense commercial success, with Mounjaro generating $5.2 billion in global sales in Q2 alone, marking a 68% year-over-year growth. The company rationalizes the hike by citing the need to address "pricing inconsistencies" relative to other developed countries and acknowledging international political pressure. While Eli Lilly has affirmed its commitment to maintaining supply through the UK's National Health Service (NHS), the move has triggered alarm among pharmacists and is expected to create affordability barriers for private patients, introducing a reputational risk reflected in the moderately negative sentiment score. This action may also serve as a precedent, potentially signaling the beginning of a trend toward higher medicine prices in the UK and a narrowing of the transatlantic pricing gap for new pharmaceuticals, as suggested by GlobalData analysts.

Key Decisions for Investors

• Investors should update revenue models for Eli Lilly to reflect significantly higher average selling prices for Mounjaro in the UK, which could provide an upside to European sales forecasts despite potential volume impacts in the private market.
• Monitor for any regulatory or political fallout in the UK and other European markets, as the sharp price increase and resulting negative sentiment could lead to governmental scrutiny or policy actions against pharmaceutical pricing power.
• Consider this a potential bellwether for other multinational pharmaceutical companies, who may be emboldened to pursue similar price normalization strategies in ex-US markets, altering the profitability outlook for the sector.